Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Febuxostat Related Intermediates: Febuxostat CAS 144060-53-7 Ethyl 2-Chloroacetoacetate CAS 609-15-4 4-Hydroxythiobenzamide CAS 25984-63-8 Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3 Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7 Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2 Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4 Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5Item | Specifications |
Appearance | Pale Yellow Solid Powder |
Purity / Analysis Method | >99.0% (HPLC) |
Identification | By HPLC; By HNMR |
Loss on Drying | <0.50% |
Residue on Ignition | <0.20% |
Single Impurity | <0.50% |
Total Impurities | <1.00% |
Test Standard | Enterprise Standard |
Usage | Intermediate of Febuxostat (CAS: 144060-53-7) |
Description:
Specifications:
Package & Storage:
Chemical Name | 4-Hydroxythiobenzamide |
Synonyms | p-Hydroxythiobenzamide; 4-Hydroxy-thiobenzamide; p-Hydroxythio-benzamide; 4-Hydroxybenzenecarbothioamide; 4-Hydroxybenzothioamide |
CAS Number | 25984-63-8 |
CAT Number | RF-PI1855 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C7H7NOS |
Molecular Weight | 153.20 |
Melting Point | 181.0~185.0℃ |
Density | 1.338±0.06 g/cm3 |
Solubility (Soluble in) | Soluble in Methanol |
Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
4-Hydroxythiobenzamide (CAS: 25984-63-8) can be used as an intermediate of Febuxostat (CAS: 144060-53-7). Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues.